سعر انهيباميت 12.5 / 1000 مجم 30 قرص 2025

Inhibamet 12.5/1000 mg (Hikma Pharma): film-coated tablets of alogliptin 12.5 mg (DPP-4 inhibitor) with metformin hydrochloride 1000 mg (biguanide), 30 tablets.

• Adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus; not for type 1 diabetes.Population: AdultsDailyMed (U.S. National Library of Medicine)

• Most common (>=4%): upper respiratory tract infection, nasopharyngitis, diarrhoea, hypertension, headache, back pain and urinary tract infection.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Severe renal impairment (eGFR below 30 mL/min/1.73 m2); acute or chronic metabolic acidosis including diabetic ketoacidosis; history of serious hypersensitivity to alogliptin, metformin or excipients (anaphylaxis, angioedema, severe skin reactions).International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Boxed warning - lactic acidosis: postmarketing metformin-associated lactic acidosis has been fatal; risk factors include renal impairment, contrast imaging, age 65+, surgery, hypoxia, excessive alcohol and hepatic impairment; stop the drug and hospitalise if suspected.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Acute pancreatitis (discontinue if suspected); heart failure risk (consider before use in at-risk patients); serious hypersensitivity including Stevens-Johnson syndrome; hepatic failure reports (interrupt if liver injury).International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Vitamin B12 deficiency with metformin; hypoglycaemia when combined with insulin or insulin secretagogues (lower their dose); severe disabling arthralgia and bullous pemphigoid with DPP-4 inhibitors.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Carbonic anhydrase inhibitors (e.g. topiramate, acetazolamide)May increase the risk of lactic acidosis; consider more frequent monitoring.DailyMed (U.S. National Library of Medicine)
• Drugs reducing metformin clearance (ranolazine, vandetanib, dolutegravir, cimetidine)May increase metformin accumulation; weigh benefits and risks.DailyMed (U.S. National Library of Medicine)
• AlcoholPotentiates the effect of metformin on lactate metabolism; avoid excessive intake.DailyMed (U.S. National Library of Medicine)

• Limited data with the combination or alogliptin are insufficient to inform drug-associated risk; published metformin studies show no clear association with major birth defects or miscarriage; poorly controlled diabetes carries maternal and fetal risks.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• No information on alogliptin in human milk (present in rat milk); metformin is present in human milk in limited studies; weigh breastfeeding benefits against the mother's need for the drug.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Alogliptin: Inhibits DPP-4, slowing inactivation of incretin hormones (GLP-1, GIP) and so increasing glucose-dependent insulin release and lowering glucagon.
• Metformin hydrochloride: Decreases hepatic glucose production, decreases intestinal glucose absorption and improves insulin sensitivity.